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Patients with high-risk acute leukemia or those
who have relapsed leukemia should receive allo-
geneic hematopoietic stem cell transplantation
(allo-HSCT) in an attempt to cure.1 Unfortunately,
allo-HSCT may not be an option for some patients
due to lack of human leukocyte antigen (HLA)-
matched donors, siblings or matched-unrelated.2
To increase the donor pool, investigators have con-
ducted clinical trials using partially-mismatched
related donors as sources of allogeneic stem cells
for transplantations.3 However, the disparity in
HLA leads to uncontrolled graft-versus-host dis-
ease (GVHD).4 Although the severity of GVHD
may be reduced by ex vivo removal of T cells from
the stem cell harvest, T cell depletion is associated
with delay or failure of sustained engraftment
and immune reconstitution as well as higher 
relapse risk.5
The underlying alloreactivity of GVHD is not
well understood. Nonetheless, CD4+ T cells ap-
pear to play a central role in orchestrating the
immune response to class II HLA molecules by
initiating a number of effecter mechanisms.6
Furthermore, experience with renal and heart
transplantation shows that transfusion of HLA-DR
matched blood components before transplanta-
tion was associated with a lower incidence of
graft rejection.7,8 The current hypothesis for this
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lower incidence of rejection is that CD4+ regula-
tory T cells that recognize a foreign peptide in
the context of the shared HLA-DR molecules
play an important role in downregulation of the
immune response toward the graft.9 Based on
these findings, we hypothesized that the HLA
barrier between recipients and both their HLA-
DR antigen-matched parental donors could be
largely eliminated. Here, we present our pilot 
experience in eight patients with high-risk acute
leukemia who underwent allo-HSCT from pa-
rental donors with matched HLA-DR antigens.
Methods
Patients and their parents had HLA-A, B, and DR
antigens determined by standard serological tech-
niques and donors were selected providing that
HLA-DR matched. The donors were given 10 μg/kg
of granulocyte-colony stimulating factor (G-CSF)
(Filgrastim; Kirin Pharma, Japan) daily for 5 days.
Peripheral blood stem cells were collected on
days 5 and 6. The collected peripheral blood stem
cells were not manipulated in vitro.
The conditioning regimen consisted of either
fractional total body irradiation (total 1200 cGy
given on days −6 to −4, patients 1 and 2) or
busulfan (4 mg/kg orally in divided doses daily
on days −7 to −4, total 16 mg/kg, patients 3–8)
combined with cyclophosphamide (60 mg/kg/day
intravenously on days −3 and −2) and fludara-
bine (Fludara; Intendis Manufacturing S.P.A, Italy;
30 mg/m2/day intravenously on days −8 to −4).
GVHD prophylaxis included rabbit antithymo-
cyte immunoglobulin (Thymoglobulin; Genzyme,
France; 2.5 mg/kg/day on days −3 to −1), cy-
closporine (Sandimmun; Novartis, Switzerland;
3 mg/kg/day intravenously starting on day −1)
and short course methotrexate (15 mg/m2 intra-
venously on day +2, 10 mg/m2 on days +4, +7
and +12). G-CSF 300 μg daily was given from
day +5 until the absolute neutrophil count ex-
ceeded 1 × 109/L. Cytomegalovirus (CMV) pp65
antigenemia analysis as reported previously was
performed weekly on peripheral nucleated cells
from the day of engraftment to day +100 for pre-
emptive therapy.10,11 The bone marrow study was
repeated after hematopoietic recovery to deter-
mine the post-transplantation disease status and
donor chimerism.
Results
The characteristics of the eight patients are sum-
marized in Table 1. All patients either had cyto-
genetic abnormalities making them at poor risk
for cure or had relapses, thus, they had very low
chances of cure with conventional chemotherapy
alone. All patients lacked fully HLA-matched sib-
lings as donors and searching failed to identify
matched unrelated donors through the hemato-
poietic stem cell donor registry. The donors were
four mothers and four fathers. HLA incompati-
bility for GVHD direction included two loci mis-
matches in five patients, and one loci mismatch
in three patients. Seven patients had identical
serological HLA-DR types with their donors. For
the remaining patient (patient 6), HLA-DR anti-
gens, DR11 of the donor and DR12 of the patient,
belonged to the same antigen of original broad
specificities, DR5 (http://www.anthonynolan.org.
uk/HIG/lists/broad.html), and was also included
in this report.
The transplantation courses and outcomes are
summarized in Table 2. The median CD34+ cell
number infused was 5.70 × 106 cells/kg weight
(range, 1.96–8.75 × 106). Hematopoietic recovery
was rapid. The median time to achieve an ab-
solute neutrophil count of more than 0.5 × 109/L
was 12 days (range, 11–16 days); the time to
achieve an absolute platelet count of greater than
20 × 109/L was 15.5 days (range, 11–31 days). All
patients achieved complete donor chimerism,
which was confirmed by sex chromosome analy-
sis or short tandem repeat polymorphism analy-
sis of bone marrow cells. No patient had graft
rejection or graft failure.
The two patients who had refractory disease
before transplantation achieved disease remis-
sion after transplantation. Only one patient had
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Table 1. Demographic details of patients
Patient
1 2 3 4 5 6 7 8
Age (yr) 20 16 19 24 23 27 25 25
Sex M M M F F M M F
Diagnosis ALL, pre-B ALL, early AML, M1 ALL, pre-B AML, M2 AML, M4 AML, M1 ALL, 
pre-B pre-B
Cytogenetics Complex Normal Normal t(9;22) t(7;11) Trisomy 8 Complex 11q-
Disease status CR2 Refractory, CR2 CR1 CR1 Relapse, CR1 CR2
(morphology) primary refractory
Diagnosis to 42 11 12 5 8 19 6 9
HSCT (mo)
Donor (age, yr) Mother Mother Father Father Father Mother Father Mother 
(51) (46) (48) (52) (53) (66) (52) (52)
HLA disparity
HVG 2 1 1 1 0 2* 2 2
GVH 1 1 2 2 2 2* 1 2
*With disparity at the DR locus. ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; CR = complete remission; HSCT = hematopoietic
stem cell transplant; HLA = human leukocyte antigen; HVG = host-versus-graft; GVH = graft-versus-host.
Table 2. Transplantation courses and outcomes
Patient
1 2 3 4 5 6 7 8
CD34+ cell (106/kg) 4.75 5.82 3.65 5.58 7.03 1.96 8.75 8.18
ANC recovery* 16 12 15 11 12 12 13 11
PLT recovery* 31 20 16 11 11 15 16 12
CMV
Reactivation – – – + – – + +
Frank disease – – – – – – + +
GVHD
Acute (grade) 0 0 0 1 0 0 0 4
Chronic Extensive† 0 NE 0 0 Limited NE 0
Leukemia status
Post-HSCT CR CR CR CR CR CR CR CR
Final CCR Relapse CR Relapse Relapse CCR CR CCR
(day +113) (day +350) (day +355)
Outcomes
Survival +48 mo 149 d 97 d 15 mo +43 mo‡ +39 mo 93 d +18 mo
Cause of death – Relapse Fungal Relapse – – CMV –
pneumonia pneumonitis
*Days to reach ANC > 0.5 × 109/mL and platelet count > 20 × 109/mL; †after donor leukocyte infusion for suspicious early relapse on day +142; ‡CR achieved
after salvage chemotherapy and donor lymphocyte infusion. ANC = absolute neutrophil count; PLT = platelets; CMV = cytomegalovirus; GVHD = graft-
versus-host disease; HSCT = hematopoietic stem cell transplant; Ext = extensive; NE = not evaluable; CR = complete remission; CR1 = first CR; CR2 =
second CR; CCR = continuous CR; SCT = stem cell transplantation.
acute GVHD of more than grade 1 that was then
controlled by corticosteroid therapy. Among the
six evaluable patients who survived beyond 100
days, two had chronic GVHD. Three patients had
CMV reactivation and received gancyclovir pre-
emptive therapy. Unfortunately, CMV reactiva-
tion progressed in one patient who died due to
documented CMV pneumonitis before D + 100.
The other patient died within the first 100 days
after transplantation due to Aspergillus pneumo-
nia. Three patients had disease relapse on days
113, 350, and 355, respectively. One of these
three patients obtained subsequent complete re-
mission after salvage chemotherapy followed by
donor lymphocyte infusion (patient 5). The
other three patients remained disease free and 
all of them experienced acute or chronic GVHD.
With the median follow-up duration of 39
months, the overall survival rate was 50.0% and
the relapse-free survival was 37.5% (Figure).
Discussion
From this pilot study, the high engraftment rate
and low incidence of severe GVHD suggest that
sharing both HLA-DR loci is associated with im-
munologic tolerance. The differential influence
of HLA-DR-matching versus HLA-A, B has also
been addressed recently in a renal transplantation
study which showed the association between
fully HLA-DR compatible grafts and lower graft
rejection rate, which is compatible with our hy-
pothesis.12 Furthermore, in our patients, the HLA
barrier can be easily overcame by an easy and tol-
erable conditioning regimen and GVHD prophy-
laxis, which are feasible in most transplantation
units, without the need of T-cell depletion or
other cell manipulations that are usually avail-
able primarily in academic transplantation cen-
ters. This advantage gives this procedure, if can
be further confirmed, even higher potency be-
cause of low threshold of facility or laboratory
requirements.
The serological HLA typing in this report may
be challenged because these patients may not be
truly HLA-DR matched with their donors if meth-
ods of higher resolution were used. However, in
our series, the risk of GVHD or graft failure was
low, suggesting that the immunotolerance was
adequate. Besides, the goal of this strategy is to
expand the donor pool by overcoming the HLA
barrier rather and to decrease GVHD by perfect
HLA matching. Thus, higher resolution of HLA
typing to differentiate the HLA-DR alleles may
not be needed in this clinical setting.
Although the series is too small to make a
solid conclusion, it suggests that allo-HSCT from
parental donors sharing HLA-DR loci may be 
feasible under an ATG- and fludarabine-based
conditioning regimen for selected patients with
high-risk leukemia who lack other fully HLA-
matched donors. This therapy warrants a larger
confirmatory study to better characterize the
technique.
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